AlzeCure Pharma
STOCKHOLM, SE / ACCESSWIRE / October 11, 2021 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at Redeye Neurology (CNS) Seminar on October 13 at 10:55 CEST, where CSO Johan Sandin will present the company's latest developments. The presentation will be followed by a panel discussion together with representatives from AlziNova and BioArctic and moderated by Redeye's analysts.
The presentation will be held in English and live streamed via https://www.redeye.se/events/815803/neurology-seminar-cns-3 . The presentation will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.
Image Attachments
Johan Sandin CSO AlzeCure Pharma
Attachments
AlzeCure presents at Redeye Neurology (CNS) Seminar on October 13
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/667525/AlzeCure-Presents-at-Redeye-Neurology-CNS-Seminar-on-October-13
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Polaris Renewable Energy Announces New Credit Facility, Executive Enhancements & Q3-25 Earnings Conference Call14.10.2025 13:50:00 CEST | Press release
TORONTO, ONTARIO / ACCESS Newswire / October 14, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce that it has entered into a US$3.5 Million Working Capital & a US$10.0 Million Letter of Credit Facility (the Facility) with the Canadian Imperial Bank of Commerce (CIBC) and the Export Development Canada (EDC). The Facility will enhance Polaris' liquidity as it continues to work towards growing its current footprint in Latin America and the Caribbean. CIBC has been the lead Banker for Polaris in Canada since 2015, while the EDC has also supported the Company in the past with similar facilities. The Company is also pleased to announce changes to its Named Executive Officers effective October 9th, as follows: Anton Jelic, CFO of the Company since December 2018 will be moving to a new role as Chief Administrative Officer to focus on Polaris' continuing growth in such key areas as IT, AI, Human Resources, Risk and continuing to strengthen Corpo
From Manual to Autonomous: Agentic CMS Automates Governance, Compliance, and Content Maintenance14.10.2025 09:00:00 CEST | Press release
Kontent.ai unveils the first CMS built for the AI era - automating governance, compliance, translations, and large-scale updates so teams can focus on creativity and growth. BRNO, CZ / ACCESS Newswire / October 14, 2025 / Across industries, marketing and content teams are being asked to achieve more with fewer resources. Yet expectations for faster publishing, more content and consistency keep rising.AI Agent reviewing thousands of content items AI Agent reviewing entire content repository for specific terms Under that pressure, generative AI has burst onto the scene, reshaping how content is created and discovered. Large language models (LLMs) and generative search experiences are redefining what customers see, hear, and believe about brands. But without structure and governance, AI can easily create more noise than value by diluting tone and introducing compliance risks. Agentic CMS was created to solve this tension. As the world's first agentic content management system, Kontent.ai'
Padcom and General Holdings Sign Term Sheet for USD 55 Million Structured Investment13.10.2025 15:00:00 CEST | Press release
RUSSELL, MB AND DUBAI, UAE, NY / ACCESS Newswire / October 13, 2025 / Potash and Agri Development Corporation of Manitoba Ltd. ("Padcom") and General Holdings Limited ("General Holdings"), a Dubai International Financial Centre (DIFC)-based private investment platform, are pleased to announce the signing of a US$55 million structured investment term sheet. The transaction outlines Padcom's next stage of expansion and General Holdings' continued focus on sustainable industrial and resource-linked investments. The transaction was originated by North Mountain Capital, which introduced the opportunity to General Holdings. Under the term sheet, General Holdings proposes to invest US$18.25 million as a Senior Secured Loan (Tranche 1) and US$36.75 million as Series A Preferred Equity (Tranche 2), with full warrant coverage. The proceeds will be used to expand Padcom's production capacity to 250,000 tonnes per annum of potash and related products, with an intended public listing targeted withi
TripGift(R) Unlocks Glocal Bucket List' Dreams With Launch of New Destination Gift Card SKUs and Marketplaces for Cities, Destinations and Experiences10.10.2025 09:00:00 CEST | Press release
Travel Commerce Innovation Winner delivers New York, Los Angeles, Miami, London, Paris, Dubai, Tokyo Destination Marketplaces and Bucket List Experience Packages in 103 currencies. NEW YORK CITY, NY / ACCESS Newswire / October 10, 2025 / TripGift®, the international multi-award-winning leader in multi-brand, multi-currency closed-loop travel gift cards and digital experience redemption marketplace, today announced the launch of a new line of Bucket List Destination Gift Cards and Marketplaces. Featuring the world's most sought-after cities-New York, London, Paris, Dubai, Tokyo and many more -these gift cards, promo vouchers and marketplaces deliver a unique, flexible and personalized value proposition and destination-themed closed-loop gifting and redemption experience.TripGift Destination Gift Cards Destination Gift cards from TripGift® Leveraging TripGift's recent 'Travel Commerce Innovation of the Year Award' and its robust technology, these personalized gift cards provide truly tar
GSK Unveils Fast-Tracked IBP Transformation with OMP at Gartner Supply Chain Planning Summit9.10.2025 17:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / October 9, 2025 / OMP, a leader in supply chain planning solutions, is spotlighting at the Gartner Supply Chain Planning Summit 2025 in London how GSK is accelerating its global transformation. The global healthcare company will reveal how it is reshaping end-to-end planning across its Medicines & Vaccines business. Powered by OMP's AI-driven Unison Planning™, GSK is speeding up demand and supply implementations worldwide. GSK's roadmap to accelerated IBP transformation Tim Shaw, Global Head of Supply Chain Planning CoE at GSK, will share how the company mobilized resources in just four months to reimagine integrated planning. Discover how GSK balanced rapid value delivery with strong IBP foundations, and built a roadmap to accelerate results while ensuring long-term transformation success. The presentation follows an executive session by John Saxby, Senior Vice President, Supply Chain at GSK, offering participants a broader view of the company's IBP j
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom